Abstract
The aim of our study was to investigate the potential of rutin, catechin, dehydrozingerone, naringenin, and quercetin, both alone and in combination with temozolomide, to inhibit the expression of O6-methylguanine-DNA methyltransferase (MGMT) in glioma cells. MGMT has been shown to be a major cause of temozolomide resistance in glioma. Our study used both in silico and in vitro methods to assess the inhibitory activity of these phytochemicals on MGMT, with the goal of identifying the most effective combination of compounds for reducing temozolomide resistance. After conducting an initial in silico screening of natural compounds against MGMT protein, five phytochemicals were chosen based on their high docking scores and favorable binding energies. From the molecular docking and simulation studies, we found that quercetin showed a good inhibitory effect of MGMT with its high binding affinity. C6 glioma cells showed increased cytotoxicity when treated with the temozolomide and quercetin combination. It was understood from the isobologram and combination index plot that the drug combination showed a synergistic effect at the lowest dose. Quercetin when combined with temozolomide significantly decreased the MGMT levels in C6 cells in comparison with the other drugs as estimated by ELISA. The percentage of apoptotic cells increased significantly in the temozolomide–quercetin group indicating the potency of quercetin in decreasing the resistance of temozolomide as confirmed by acridine orange/ethidium bromide staining. Our experiment hence suggests that temozolomide resistance can be reduced by combining the drug with quercetin which will serve as an effective therapeutic target for glioblastoma treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Data will be provided on request.
References
Arfan M, Khan R, Rybarczyk A, Amarowicz R (2012) Antioxidant activity of mulberry fruit extracts. Int J Mol Sci 13(2):2472–2480. https://doi.org/10.3390/ijms13022472
Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K, Avan A (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233(1):378–386. https://doi.org/10.1002/jcp.25896
Cavenee WK, Louis DN, Ohgaki H, Wiestler OD (2007) WHO classification of tumors of the central nervous system, vol 1. WHO Regional Office Europe
Chen TJ, Jeng JY, Lin CW, Wu CY, Chen YC (2006) Quercetin inhibition of ROS-dependent and -independent apoptosis in rat glioma C6 cells. Toxicology 223(1–2):113–126. https://doi.org/10.1016/j.tox.2006.03.007
Chikan NA, Bukhari S, Shabir N, Amin A, Shafi S, Qadri RA, Patel TN (2015) Atomic insight into the altered o6-methylguanine-DNA methyltransferase protein architecture in gastric cancer. PLoS ONE 10(5):e0127741. https://doi.org/10.1371/journal.pone.0127741
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. https://doi.org/10.1016/0065-2571(84)90007-4
Chou TC, Martin N, (2005) CompuSyn for drug combinations: PC software and user’s guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. ComboSyn Inc, Paramus, NJ
Craig WJ (1997) Phytochemicals: guardians of our health. J Am Diet Assoc 97(10 Suppl 2):S199-204. https://doi.org/10.1016/s0002-8223(97)00765-7
Danciu C, Pinzaru IA, Dehelean CA, Hancianu M, Zupko I, Navolan D, Licker M, Ghiulai RM, Şoica CMJF (2018) Antiproliferative and antimicrobial properties of pure and encapsulated rutin. FARMACIA (BUCHAREST) 66(2):302–308
Daniels DS, Mol CD, Arvai AS, Kanugula S, Pegg AE, Tainer JA (2000) Active and alkylated human AGT structures: a novel zinc site, inhibitor, and extrahelical base binding. EMBO J 19(7):1719–1730. https://doi.org/10.1093/emboj/19.7.1719
Davis B, Shen Y, Poon CC, Luchman HA, Stechishin OD, Pontifex CS, Wu W, Kelly JJ, Blough MD, Terry Fox Research Institute Glioblastoma C (2016) Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors. Neuro Oncol 18 (3):350-360. doi:https://doi.org/10.1093/neuonc/nov143
Dhawan S, Kapil R, Singh B (2011) Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 63(3):342–351. https://doi.org/10.1111/j.2042-7158.2010.01225.x
Duke JA (1992) Handbook of biologically active phytochemicals and their activities. CRC Press Inc, Boca Raton
Enkhmaa B, Shiwaku K, Katsube T, Kitajima K, Anuurad E, Yamasaki M, Yamane Y (2005) Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice. J Nutr 135(4):729–734. https://doi.org/10.1093/jn/135.4.729
Farha AK, Gan RY, Li HB, Wu DT, Atanasov AG, Gul K, Zhang JR, Yang QQ, Corke H (2022) The anticancer potential of the dietary polyphenol rutin: current status, challenges, and perspectives. Crit Rev Food Sci Nutr 62(3):832–859. https://doi.org/10.1080/10408398.2020.1829541
Fujiki H, Suganuma M, Imai K, Nakachi K (2002) Green tea: cancer preventive beverage and/or drug. Cancer Lett 188(1–2):9–13. https://doi.org/10.1016/s0304-3835(02)00379-8
Gautam M, Gabrani R (2022) Combinatorial effect of temozolomide and naringenin in human glioblastoma multiforme cell lines. Nutr Cancer 74(3):1071–1078. https://doi.org/10.1080/01635581.2021.1952438
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449–461. https://doi.org/10.1517/17460441.2015.1032936
Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10(6):1871–1874. https://doi.org/10.1158/1078-0432.ccr-03-0384
Hospital A, Goni JR, Orozco M, Gelpi JL (2015) Molecular dynamics simulations: advances and applications. Adv Appl Bioinform Chem 8:37–47. https://doi.org/10.2147/AABC.S70333
Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ, Zheng JN (2011) A novel approach to overcome temozolomide resistance in glioma and melanoma: inactivation of MGMT by gene therapy. Biochem Biophys Res Commun 406(3):311–314. https://doi.org/10.1016/j.bbrc.2011.02.042
Johnson IT (2007) Phytochemicals and cancer. Proc Nutr Soc 66(2):207–215. https://doi.org/10.1017/S0029665107005459
Khatun B, Kamath V, Muddukrishna BS, Pai A (2020) Extra precision docking and adme simulation studies on novel analogues of pyrazoles as anticancer leads. Manipal J Pharma Sci 6(1):41–46
Kubota H, Nishizaki T, Harada K, Harada K, Oga A, Ito H, Suzuki M, Sasaki K (2001) Identification of recurrent chromosomal rearrangements and the unique relationship between low-level amplification and translocation in glioblastoma. Genes Chromosomes Cancer 31(2):125–133. https://doi.org/10.1002/gcc.1126
Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3(3):198–210. https://doi.org/10.1016/j.gendis.2016.04.007
Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, Rosenblum M, Mikkelsen T, Zenklusen JC, Fine HA (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6(1):21–30. https://doi.org/10.1158/1541-7786.MCR-07-0280
Li M, Liang RF, Wang X, Mao Q, Liu YH (2017) BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-kappaB/MGMT signaling pathway. Oncol Lett 14(6):6597–6603. https://doi.org/10.3892/ol.2017.7034
MacKerell AD, Wiorkiewicz-Kuczera J, Karplus M (2002) An all-atom empirical energy function for the simulation of nucleic acids. J Am Chem Soc 117(48):11946–11975. https://doi.org/10.1021/ja00153a017
Moody CL, Wheelhouse RT (2014) The medicinal chemistry of imidazotetrazine prodrugs. Pharmaceuticals (Basel) 7(7):797–838. https://doi.org/10.3390/ph7070797
Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J (2008) A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61(4):653–659. https://doi.org/10.1007/s00280-007-0520-x
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development, and clinical trials. Cancer Treat Rev 23(1):35–61. https://doi.org/10.1016/s0305-7372(97)90019-0
Pai A, Jayashree B, Basu-Mallik S, Lobo R (2017) Extra precision Docking studies of novel Luteolin analogues for the inhibition of Tankyrase II-“a theoretical based approach towards novel cancer target. Thai J Pharm Sci 41(4):138–143
Pathak N, Cheruku SP, Rao V, Vibhavari RJA, Sumalatha S, Gourishetti K, Rao CM, Kumar N (2020) Dehydrozingerone protects temozolomide-induced cognitive impairment in normal and C6 glioma rats besides enhancing its anticancer potential. 3 Biotech 10(10):438. https://doi.org/10.1007/s13205-020-02427-7
Pegg AE, Boosalis M, Samson L, Moschel RC, Byers TL, Swenn K, Dolan ME (1993) Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry 32(45):11998–12006. https://doi.org/10.1021/bi00096a009
Quirt I, Verma S, Petrella T, Bak K, Charette M (2007) Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 12(9):1114–1123. https://doi.org/10.1634/theoncologist.12-9-1114
Rajakumar DV, Rao MN (1994) Antioxidant properties of dehydrozingerone and curcumin in rat brain homogenates. Mol Cell Biochem 140(1):73–79. https://doi.org/10.1007/BF00928368
Rao V, Cheruku SP, Manandhar S, Vibhavari RJA, Nandakumar K, Rao CM, Ravichandiran V, Kumar N (2021) Restoring chemo-sensitivity to temozolomide via targeted inhibition of poly (ADP-ribose) polymerase-1 by naringin in glioblastoma. Chem Pap 75(9):4861–4871. https://doi.org/10.1007/s11696-021-01700-0
Rathi E, Kumar A, Kini SG (2019) Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors. J Recept Signal Transduct Res 39(5–6):415–433. https://doi.org/10.1080/10799893.2019.1690509
Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB (1995) The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res 22(4):375–383. https://doi.org/10.3109/10715769509145649
Salehi B, Fokou PVT, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, Sharifi-Rad J (2019) The Therapeutic potential of naringenin: a review of clinical trials. Pharmaceuticals (basel) 12(1):11. https://doi.org/10.3390/ph12010011
Sang DP, Li RJ, Lan Q (2014) Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. Acta Pharmacol Sin 35(6):832–838. https://doi.org/10.1038/aps.2014.22
Santos BL, Silva AR, Pitanga BP, Sousa CS, Grangeiro MS, Fragomeni BO, Coelho PL, Oliveira MN, Menezes-Filho NJ, Costa MF, El-Bacha RS, Velozo ES, Sampaio GP, Freire SM, Tardy M, Costa SL (2011) Antiproliferative, proapoptotic and morphogenic effects of the flavonoid rutin on human glioblastoma cells. Food Chem 127(2):404–411. https://doi.org/10.1016/j.foodchem.2010.12.131
Satarker S, Maity S, Mudgal J, Nampoothiri M (2022) In silico screening of neurokinin receptor antagonists as a therapeutic strategy for neuroinflammation in Alzheimer’s disease. Mol Divers 26(1):443–466. https://doi.org/10.1007/s11030-021-10276-6
Schrödinger L (2016a) Glide, Version 7.1. Schrödinger, LLC, New York, NY
Schrödinger L (2016b) Schrödinger Release 2016–2: LigPrep Version. vol 20167. Schrödinger, LLC, New York
Schrödinger L (2016c) Schrödinger Suite. Schrödinger, LLC, New York
Schrödinger L (2016d) Small-Molecule Drug Discovery Suite 2016–1: Qikprop. Schrödinger, LLC, New York
Segel I (1975) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley, New York. https://doi.org/10.1016/0014-5793(75)80457-1
Sharma B, Bhattacherjee D, Zyryanov GV, Purohit R (2022) An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders. J Biomol Struct Dynam. https://doi.org/10.1080/07391102.2022.2141895
Smith SW (1982) A model of labeled-ligand displacement assays resulting in logit-log relationships. J Theor Biol 98(3):475–499. https://doi.org/10.1016/0022-5193(82)90132-1
Stupp R, Hegi ME, Idbaih A, Steinberg DM, Lhermitte B, Read W, Toms SA, Barnett GH, Nicholas G, Kim C-Y (2017) Abstract CT007: tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multi-center, phase III trial. Cancer Res 13_Supplement. https://doi.org/10.1158/1538-7445.AM2017-CT007
Sun YS (2018) Direct-current electric field distribution in the brain for tumor treating field applications: a simulation study. Comput Math Methods Med 2018:3829768. https://doi.org/10.1155/2018/3829768
Sun G, Fan T, Zhang N, Ren T, Zhao L, Zhong R (2016) Identification of the structural features of guanine derivatives as mgmt inhibitors using 3D-QSAR modeling combined with molecular docking. Molecules 21(7):823. https://doi.org/10.3390/molecules21070823
Taylor MA, Khathayer F, Ray SK (2019) Quercetin and sodium butyrate synergistically increase apoptosis in rat C6 and human T98G glioblastoma cells through inhibition of autophagy. Neurochem Res 44(7):1715–1725. https://doi.org/10.1007/s11064-019-02802-8
Tiwari A, Gopalan Kutty N, Kumar N, Chaudhary A, Vasanth Raj P, Shenoy R, Mallikarjuna Rao C (2016) Synthesis and evaluation of selected 1,3,4-oxadiazole derivatives for in vitro cytotoxicity and in vivo anti-tumor activity. Cytotechnology 68(6):2553–2565. https://doi.org/10.1007/s10616-016-9979-9
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116. https://doi.org/10.1038/nprot.2006.179
Villano JL, Seery TE, Bressler LR (2009) Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64(4):647–655. https://doi.org/10.1007/s00280-009-1050-5
Wesolowski JR, Rajdev P, Mukherji SK (2010) Temozolomide (Temodar). AJNR Am J Neuroradiol 31(8):1383–1384. https://doi.org/10.3174/ajnr.A2170
Xu HU, Bihari F, Whitehead S, Wong E, Schmid S, Hebb MO (2016) In vitro validation of intratumoral modulation therapy for glioblastoma. Anticancer Res 36(1):71–80
Yoshizawa S, Horiuchi T, Fujiki H, Yoshida T, Okuda T, Sugimura TJPR (1987) Antitumor promoting activity of (−)-epigallocatechin gallate, the main constituent of “Tannin” in green tea. Phytother Res 1(1):44–47
Zhang Y, Wang SX, Ma JW, Li HY, Ye JC, Xie SM, Du B, Zhong XY (2015) EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J Neurooncol 121(1):41–52. https://doi.org/10.1007/s11060-014-1604-1
Zhang N, Fu JN, Chou TC (2016) Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am J Cancer Res 6(1):97–104
Zhang P, Sun S, Li N, Ho ASW, Kiang KMY, Zhang X, Cheng YS, Poon MW, Lee D, Pu JKS, Leung GKK (2017) Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. J Neurooncol 132(3):393–400. https://doi.org/10.1007/s11060-017-2387-y
Acknowledgements
We sincerely thank Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, for providing all the facilities and funding for our research work. We thank Schrodinger Centre for Molecular Simulations, and the Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences for assisting in computer simulation studies (DST_SERB, New Delhi, India EMR/2016/007006).
Funding
Intramural Fund (IMF) (Grant No. MAHE/DREG/PhD/IMF/2019) provided by Manipal Academy of Higher Education, Manipal.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Vibhavari, R.J.A., Rao, V., Cheruku, S.P. et al. Enhancing temozolomide antiglioma response by inhibiting O6-methylguanine-DNA methyltransferase with selected phytochemicals: in silico and in vitro approach. 3 Biotech 13, 385 (2023). https://doi.org/10.1007/s13205-023-03821-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-023-03821-7